{"id":230338,"date":"2026-02-02T09:08:10","date_gmt":"2026-02-02T15:08:10","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/high-risk-epn-models-present-the-immunotherapeutic-target-gd2-and-are-sensitive-to-gd2-car-t-cell-therapy-in-vitro-and-in-vivo"},"modified":"2026-02-02T09:08:10","modified_gmt":"2026-02-02T15:08:10","slug":"high-risk-epn-models-present-the-immunotherapeutic-target-gd2-and-are-sensitive-to-gd2-car-t-cell-therapy-in-vitro-and-in-vivo","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/high-risk-epn-models-present-the-immunotherapeutic-target-gd2-and-are-sensitive-to-gd2-car-t-cell-therapy-in-vitro-and-in-vivo","title":{"rendered":"High-risk EPN models present the immunotherapeutic target GD2 and are sensitive to GD2\u2013CAR T cell therapy in vitro and in vivo"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/high-risk-epn-models-present-the-immunotherapeutic-target-gd2-and-are-sensitive-to-gd2-car-t-cell-therapy-in-vitro-and-in-vivo2.jpg\"><\/a><\/p>\n<p>Research Letter: CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models.<\/p>\n<p>Antonio Carlos Tallon-Cobos &amp; team establish a new ependymoma model for preclinical research and demonstrate a promising immunotherapeutic approach for this largely aggressive pediatric brain cancer.<\/p>\n<hr>\n<p>\n<sup>1<\/sup>Princess M\u00e1xima Center for pediatric oncology, Utrecht, Netherlands.<\/p>\n<p><sup>2<\/sup>Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.<\/p>\n<p><sup>3<\/sup>Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium (DKTK), Heidelberg, Germany.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Research Letter: CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models. Antonio Carlos Tallon-Cobos &amp; team establish a new ependymoma model for preclinical research and demonstrate a promising immunotherapeutic approach for this largely aggressive pediatric brain cancer. 1Princess M\u00e1xima Center for pediatric oncology, Utrecht, Netherlands. 2Hopp Children\u2019s Cancer Center [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-230338","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=230338"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230338\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=230338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=230338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=230338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}